Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07679607

GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung

Decreased respiratory function is a common side effect experienced by non-small cell lung cancer (NSCLC) patients who receive radiation therapy. In current clinical practice when treating cancerous lesions in the lung, it is not standard to explicitly try and avoid excessive radiation dose and therefore radiation injury to smaller airways. However, because of this patients may obtain damage to an airway segment can cause downstream regions in the lung to lose their "supply line" and, therefore, cause patients to lose the ability to exchange oxygen with the blood. The purpose of this clinical trial is to systematically compare post-treatment lung function of those who receive regular clinical radiation therapy (standard of care [SoC]) versus those who receive the airway-sparing radiation therapy regimen. The investigators hope to show that, by preserving airways and connected lung regions, participants will be able to retain a larger amount of their lung function, which will have a direct, positive impact on their post-treatment quality of life.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Maryland Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States

Location contact

Caitlin Eggleston, MPH

CONTACT

[email protected]

410-369-5351

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Step 1- Inclusion Criteria
  • Adult (≥18 years) patients (both sexes) with histologically diagnosed Stage III NSCLC per AJCC ver 9
  • Patients to be treated with definitive external beam photon radiotherapy with or without systemic therapy (e.g., chemothrapy, immunotherapy).
  • No restrictions on number radiotherapy fractions, or location/number of lesions
  • ECOG performance status ≤ 3
  • Ability to hold breath for ≥ 15 seconds
  • Patient has signed informed consent document and agreed to study procedures

Step 2- Inclusion Criteria 1. Patient has completed 4DCT and BHCT with subsequent plans created and Radiation Oncologist has determined that patient would benefit from INSPIRE RT.

Exclusion criteria

  • Step 1- Exclusion Criteria
  • Prior lung cancer-directed radiotherapy
  • Recent (< 12 mo) or planned lung surgery (which would confound pre- and post-RT lung function measures)
  • Patients with metal implants or metal stents in the thoracic region
  • Known severe chronic obstructive pulmonary disease or interstitial lung disease
  • Women who are pregnant or trying to get pregnant

Step 2- Exclusion Criteria

  • Patient found to not benefit from INSPIRE RT after comparison of treatment plans.

Treatment and study plan

SOC Radiation Treatment Planning

Radiation

Two treatment plans will be created for each patient - an SOC RT plan and an INSPIRE RT plan. Both plans will fulfill clinical dosimetric objectives for tumor target and OARs, and will need to be reviewed and approved by the Radiation Oncologist. The trial will allow intensity modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT). Both techniques have been validated for INSPIRE RT previously. Both plans meet clinical dosimetric objectives. The INSPIRE plan achieves the additional goal of sparing functional units by better modulating the low dose and the intermediate dose compared to the SOC plan

INSPIRE Radiation Treatment Planning

Radiation

Two treatment plans will be created for each patient - an SOC RT plan and an INSPIRE RT plan. Both plans will fulfill clinical dosimetric objectives for tumor target and OARs, and will need to be reviewed and approved by the Radiation Oncologist. The trial will allow intensity modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT). Both techniques have been validated for INSPIRE RT previously. Both plans meet clinical dosimetric objectives. The INSPIRE plan achieves the additional goal of sparing functional units by better modulating the low dose and the intermediate dose compared to the SOC plan

Primary outcomes

  1. Measurement of Post-Radiation retention of ventilation at 12 months through imaging.

    Time frame: 12 months

    The central objective of this trial is to determine if dose-sparing of airways and connected high-functioning sub-lobar lung volumes leads to superior preservation of post-RT ventilation compared to that achieved through SOC RT

Secondary outcomes

  1. Number of patients with Grade 2 or higher toxicities defined by Common Terminology Criteria for Adverse Events (CTCAE) v5

    Time frame: 12 months

    Local-regional control, radiographically-assessed change in radiation pneumonitis/lung fibrosis, Grade ≥ 2 toxicity per CTCAE definition.

Study contacts

Contact information is provided by the study sponsor or research team.

Amit Sawant, PhD

CONTACT

[email protected]

410-328-6080

Caitlin Eggleston, MPH

CONTACT

[email protected]

410-369-5351

Sponsors and collaborators

Lead sponsor

University of Maryland, Baltimore

Other

Registry information

Acronym: INSPIRE

Important dates

Study start
2026
Primary completion
2028
Study completion
2030
First posted
Jul 1, 2026
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.